Dental and medical practices
How to Sell an Independent Pharmacy
The short answer
Most independent pharmacies sell for 3.0 to 5.0 times EBITDA, with a typical midpoint around 4.0 times, and the buyer pays for inventory at cost on top of that price. Script volume, gross profit per script, payer mix, and how much of the business depends on higher-margin services like compounding, immunizations, and long-term care all move you within that range. An older rule of thumb that priced pharmacies as a percent of annual revenue is largely outdated and can badly mislead an owner, since two pharmacies with identical revenue can have very different profit once PBM reimbursement pressure and DIR fees are accounted for.
Your numbers
The numbers
Step 1 of 3
Loading your calculator…
Prefer the dedicated tool? Pharmacy Valuation Calculator
Why pharmacies are priced on EBITDA plus inventory, not a percent of revenue
For years, some pharmacy brokers used a rule of thumb that priced a pharmacy as a percentage of annual revenue, often somewhere between 15% and 25% of sales. That approach made a certain kind of sense when reimbursement was more stable and gross margins across independent pharmacies were fairly similar, but it has become an unreliable way to value a pharmacy today. Two stores doing $4 million in annual revenue can land in very different places on profit depending on their payer mix, generic dispensing rate, and how aggressively PBMs claw back margin through direct and indirect remuneration fees.
The more reliable approach, and the one this site uses, is to value the pharmacy on a multiple of EBITDA, meaning earnings before interest, taxes, depreciation and amortization, with the owner's pharmacist salary and any personal expenses normalized to a fair market rate. Typical multiples run from 3.0 to 5.0 times EBITDA, with a midpoint around 4.0 times for a well-run, average-risk pharmacy. Inventory is priced and paid for separately, usually at cost or close to it, and is not baked into the multiple.
That separation matters because inventory value can swing significantly from one pharmacy to the next and even month to month depending on ordering patterns, so folding it into an EBITDA multiple would distort the number. When you see a headline price for a pharmacy sale, always ask whether it includes inventory or is quoted separately, since the two figures together, not the multiple alone, tell you what a seller actually walks away with.
Script volume and gross profit per script
Prescription volume, usually expressed as scripts per day or scripts per month, is one of the first numbers a buyer asks for, but it is not the number that determines value on its own. What matters more is gross profit per script, since a pharmacy filling 200 scripts a day at a thin margin can generate less profit than one filling 140 scripts a day with a stronger payer mix and better generic utilization.
Buyers will want a script count trend over the past two to three years, broken out by new versus refill, and by payer type where possible. A steady or growing script count supported by a loyal patient base is viewed far more favorably than a flat or declining count propped up by a handful of large institutional accounts that could leave with little notice.
Generic dispensing rate is worth tracking closely as well, since generics typically carry a much better margin than brand-name drugs, and a pharmacy with a generic dispensing rate meaningfully below its regional peers is often leaving profit on the table that a buyer will want explained.
Payer mix, PBM reimbursement pressure, and DIR fees
Reimbursement from pharmacy benefit managers has become one of the biggest swing factors in independent pharmacy profitability, and buyers scrutinize this closely. A pharmacy heavily weighted toward a small number of PBM contracts with aggressive reimbursement terms and steep direct and indirect remuneration, or DIR, fees carries more risk than one with a more diversified payer mix, even if current profit looks similar.
Because DIR fees are often assessed and reconciled months after a prescription is filled, they can make a pharmacy's trailing financials look better than the true, current run rate. Buyers typically ask for the most recent 12 to 24 months of PBM remittance detail to understand how much of reported profit has already been or will be clawed back, and they will normalize earnings downward if recent DIR activity suggests further pressure ahead.
A pharmacy that has diversified away from pure third-party reimbursement, through cash-pay services, 340B participation where applicable, or specialty and long-term care contracts with more favorable terms, is generally viewed as a steadier business and tends to support a multiple toward the higher end of the typical range.
Front-end retail, compounding, immunizations, and long-term care
The front-end retail counter, over-the-counter products, gifts, and general merchandise, is usually a smaller piece of an independent pharmacy's profit than the prescription counter, but it still matters, particularly where it drives foot traffic and repeat visits that support script volume. Buyers will look at front-end sales as a share of total revenue and at its margin, since a well-curated front end with healthy margins is a mild positive, while a large but low-margin front end adds complexity without much profit.
Higher-margin services tend to matter more to valuation. Compounding, where legally and safely operated, can carry strong margins and differentiate a pharmacy from big-box competitors, though buyers will want to see it is compliant with state board and USP compounding standards, since compliance problems here can be costly to unwind. Immunization services, especially with strong seasonal flu and routine vaccine volume, add a recurring, relatively high-margin revenue stream that many buyers value because it is not entirely dependent on physician referral patterns.
Long-term care and assisted living contracts, where a pharmacy packages and delivers medications to facility residents, can be a meaningful part of an independent pharmacy's business and often come with more predictable, contracted revenue than walk-in retail. Buyers will look at how many facility contracts exist, how long they have run, and whether they are exclusive or could shift to a competing long-term care pharmacy with a change in facility management.
Patient file value when a chain buyer plans to close the location
Not every pharmacy sale is a continuation of the business as a going concern. In some deals, particularly where a chain pharmacy is the buyer, the buyer's real interest is acquiring the patient files and transferring those prescriptions to a nearby existing location rather than continuing to operate your store. This is sometimes called a file buy, and it is priced very differently from a going-concern sale.
In a file buy, the price is typically based on a per-file or per-script-value figure rather than an EBITDA multiple, since there is no ongoing business, staff, or lease being taken on. This can sometimes produce a faster, simpler transaction, but it usually nets a lower total price than a going-concern sale to an independent buyer who values the full business, including its lease, staff, and brand.
If you are approached by a chain interested primarily in your patient files, it is worth understanding which type of deal is on the table before comparing any offer to the multiples described elsewhere in this guide, since the two are not directly comparable. A pharmacy with strong long-term care contracts, a good location, and capable staff willing to stay on is often worth meaningfully more as a going concern than as a file buy.
Licensing, DEA registration, and change-of-ownership timing
Every pharmacy sale involves transferring or reissuing state board of pharmacy licensure and DEA registration, and the timing of this process needs to be built into your deal timeline well in advance. Requirements vary by state, but most require notice to the board before a change of ownership closes, and some require a new pharmacist-in-charge to be named and approved before the transfer is finalized.
DEA registration is tied to the specific pharmacy and owner, so a new registration or a formal change of ownership filing is typically required, and any lapse in valid registration can halt controlled substance dispensing entirely, which is disruptive to patients and costly to the business. Buyers will want a clear, realistic timeline for these approvals built into the purchase agreement, often with an escrow or holdback tied to successful license transfer.
Any outstanding compliance issues, board complaints, or controlled substance ordering pattern flags from wholesalers should be identified and, where possible, resolved before you go to market. These issues tend to surface during buyer due diligence regardless, and discovering them mid-negotiation is far more damaging to price and trust than addressing them ahead of time.
Who buys independent pharmacies
Regional and national chains sometimes buy independent pharmacies outright to continue operating them, though more often their interest is in the patient files as described above, particularly in markets where they already have a nearby store. Chains that do acquire and keep a location running tend to focus on strong script volume and a favorable lease.
Independent pharmacy operators, often owners of one or more other pharmacies looking to add a location, are common buyers for going-concern sales, particularly where the pharmacy has a loyal patient base, long-term care contracts, or a strong reputation in its community. These buyers understand the day-to-day realities of running a pharmacy and often move faster through due diligence than an outside buyer would.
Individual pharmacists buying their first store, frequently financed through an SBA 7(a) loan, remain an active part of the market for smaller, well-run pharmacies. These buyers typically need the seller to stay on for a transition period to introduce them to physicians, long-term care contacts, and patients, and lenders will often want to see stable historical earnings and a clean compliance history before approving financing.
Lease, real estate, and preparation steps before you sell
Most independent pharmacies operate from a leased location, and the lease terms, including remaining length, renewal options, and rent relative to market rates, are reviewed closely by buyers and by any SBA lender involved in financing the deal. A lease with several years remaining and reasonable rent supports a smoother sale, while a lease nearing expiration with an uncertain renewal can complicate financing and should be addressed with your landlord well before you go to market.
If you own the real estate the pharmacy operates from, decide in advance whether you plan to sell the property along with the business, lease it to the buyer going forward, or sell it separately, since each path affects how the deal is structured and how it is marketed to different types of buyers.
Before going to market, normalize your financials across the past two to three years with a clear explanation of every add-back, gather your PBM remittance detail and DIR fee history, document script volume trends and generic dispensing rate, and confirm your licensing and DEA registration are current and free of unresolved issues. Giving yourself twelve to eighteen months of lead time to organize this information and address any compliance gaps tends to produce a smoother process and a stronger outcome than trying to assemble it after a buyer has already made an offer.
A hypothetical example
Say an independent pharmacy filling around 180 scripts per day reports $5.2 million in annual revenue and $340,000 in net profit on its tax return. After normalizing the owner-pharmacist's salary to a fair market rate, adding back $30,000, and adjusting for a one-time legal expense of $12,000, EBITDA comes to about $382,000. The pharmacy has a generic dispensing rate in line with regional peers, a diversified payer mix with no single PBM contract dominating reimbursement, a modest but steady long-term care contract with a local assisted living facility, and $310,000 in prescription inventory on hand at cost. Given that profile, this hypothetical pharmacy might attract a multiple around 3.5 to 4.0 times EBITDA, implying a business value of roughly $1.34 million to $1.53 million, with the $310,000 in inventory paid on top at closing for a total transaction value of roughly $1.65 million to $1.84 million. If the same pharmacy instead had heavy reliance on one PBM contract with recent DIR fee increases and a declining script count, buyers would likely apply a multiple closer to 3.0 times, or push toward a file-buy structure altogether rather than a going-concern sale. This example is illustrative only and not a prediction of what any specific pharmacy would sell for.
Multiple ranges reviewed September 2026. They are a guide, not a quote or a formal appraisal — see how the process works.
Common questions
What multiple do independent pharmacies typically sell for?
Most independent pharmacies sell for 3.0 to 5.0 times EBITDA, with a typical midpoint around 4.0 times. Inventory is paid for separately, usually at cost, on top of that price.
Why not just price a pharmacy as a percent of revenue?
That older rule of thumb ignores how differently two pharmacies with similar revenue can perform on profit once PBM reimbursement pressure, DIR fees, and payer mix are accounted for. An EBITDA multiple plus inventory is a more reliable way to reflect actual profitability.
Is pharmacy inventory included in the sale price?
Generally no. Inventory is typically counted and paid for separately at or near cost at closing, on top of the price implied by the EBITDA multiple for the business itself.
How do DIR fees affect my pharmacy's value?
Because direct and indirect remuneration fees are often assessed months after a prescription is filled, they can make trailing financials look better than the current run rate. Buyers typically review recent PBM remittance detail and normalize earnings downward if DIR activity suggests continued pressure.
What is a file buy and how is it different from selling my pharmacy?
A file buy is when a chain buyer acquires your patient prescription files to transfer to a nearby store rather than continuing to operate your location. It is typically priced per file or per script rather than as an EBITDA multiple, and usually results in a lower total price than a going-concern sale.
Do compounding, immunizations, and long-term care contracts increase the sale price?
They often support a stronger multiple because they tend to carry higher margins and, in the case of long-term care contracts, more predictable revenue than walk-in retail, provided compliance with relevant state board and USP standards is documented.
How does DEA registration affect the timing of a pharmacy sale?
DEA registration is tied to the specific pharmacy and owner, so a change of ownership typically requires a new registration or formal transfer filing. This needs to be built into your closing timeline, since any lapse can halt controlled substance dispensing.
Who typically buys independent pharmacies?
Regional and national chains, often interested in patient files rather than continuing operations, independent pharmacy operators adding a location, and individual pharmacists using SBA financing for their first store are the most common buyer types.